Clinically-relevant postzygotic mosaicism in parents and children with developmental disorders in trio exome sequencing data.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
05 07 2019
Historique:
received: 24 01 2019
accepted: 12 06 2019
entrez: 7 7 2019
pubmed: 7 7 2019
medline: 23 10 2019
Statut: epublish

Résumé

Mosaic genetic variants can have major clinical impact. We systematically analyse trio exome sequence data from 4,293 probands from the DDD Study with severe developmental disorders for pathogenic postzygotic mosaicism (PZM) in the child or a clinically-unaffected parent, and use ultrahigh-depth sequencing to validate candidate mosaic variants. We observe that levels of mosaicism for small genetic variants are usually equivalent in both saliva and blood and ~3% of causative de novo mutations exhibit PZM; this is an important observation, as the sibling recurrence risk is extremely low. We identify parental PZM in 21 trios (0.5% of trios), resulting in a substantially increased sibling recurrence risk in future pregnancies. Together, these forms of mosaicism account for 40 (1%) diagnoses in our cohort. Likely child-PZM mutations occur equally on both parental haplotypes, and the penetrance of detectable mosaic pathogenic variants overall is likely to be less than half that of constitutive variants.

Identifiants

pubmed: 31278258
doi: 10.1038/s41467-019-11059-2
pii: 10.1038/s41467-019-11059-2
pmc: PMC6611863
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2985

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00007/3
Pays : United Kingdom
Organisme : Wellcome Trust (Wellcome)
ID : WT098051
Pays : International

Commentaires et corrections

Type : ErratumIn

Références

Biesecker, L. G. & Spinner, N. B. A genomic view of mosaicism and human disease. Nat. Rev. Genet. 14, 307–320 (2013).
pubmed: 23594909 doi: 10.1038/nrg3424
Lupski, J. R. Genome mosaicism–one human, multiple genomes. Science 341, 358–359 (2013).
pubmed: 23888031 doi: 10.1126/science.1239503
Acuna-Hidalgo, R. et al. Post-zygotic point mutations are an underrecognized source of de novo genomic variation. Am. J. Hum. Genet. 97, 67–74 (2015).
pubmed: 26054435 pmcid: 4571017 doi: 10.1016/j.ajhg.2015.05.008
Campbell, I. M. et al. Parental somatic mosaicism is underrecognized and influences recurrence risk of genomic disorders. Am. J. Hum. Genet. 95, 173–182 (2014).
pubmed: 25087610 pmcid: 4129404 doi: 10.1016/j.ajhg.2014.07.003
Halvorsen, M. et al. Mosaic mutations in early-onset genetic diseases. Genet. Med. 18, 746–749 (2016).
pubmed: 26716362 doi: 10.1038/gim.2015.155
Myers, C. T. et al. Parental mosaicism in “de novo” epileptic encephalopathies. N. Engl. J. Med. 378, 1646–1648 (2018).
pubmed: 29694806 pmcid: 5966016 doi: 10.1056/NEJMc1714579
Campbell, I. M. et al. Parent of origin, mosaicism, and recurrence risk: probabilistic modeling explains the broken symmetry of transmission genetics. Am. J. Hum. Genet. 95, 345–359 (2014).
pubmed: 25242496 pmcid: 4185125 doi: 10.1016/j.ajhg.2014.08.010
Breuss, M. et al. Quantification of autism recurrence risk by direct assessment of paternal sperm mosaicism. BioRxiv. https://doi.org/10.1101/208165 (2017)
Jonsson, H. et al. Recurrence of de novo mutations in families. BioRxiv. https://doi.org/10.1101/221259 (2017)
Rahbari, R. et al. Timing, rates and spectra of human germline mutation. Nat. Genet. 48, 126–133 (2016).
pubmed: 26656846 doi: 10.1038/ng.3469
Poduri, A., Evrony, G. D., Cai, X. & Walsh, C. A. Somatic mutation, genomic variation, and neurological disease. Science 341, 1237758 (2013).
pubmed: 23828942 pmcid: 3909954 doi: 10.1126/science.1237758
Nathan, N., Keppler-Noreuil, K. M., Biesecker, L. G., Moss, J. & Darling, T. N. Mosaic disorders of the pi3k/pten/akt/tsc/mtorc1 signaling pathway. Dermatol Clin. 35, 51–60 (2017).
pubmed: 27890237 pmcid: 5130114 doi: 10.1016/j.det.2016.07.001
Ansari, M. et al. Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and CdLS-like phenotypes with observed and predicted levels of mosaicism. J. Med. Genet. 51, 659–668 (2014).
pubmed: 25125236 doi: 10.1136/jmedgenet-2014-102573
Goriely, A. et al. Germline and somatic mosaicism for FGFR2 mutation in the mother of a child with Crouzon syndrome: Implications for genetic testing in “paternal age-effect” syndromes. Am. J. Med. Genet. A 152A, 2067–2073 (2010).
pubmed: 20635358 pmcid: 2988406 doi: 10.1002/ajmg.a.33513
Xin, B. et al. Novel DNMT3A germline mutations are associated with inherited Tatton-Brown-Rahman syndrome. Clin. Genet. 91, 623–628 (2017).
pubmed: 27701732 doi: 10.1111/cge.12878
Stosser, M. B. et al. High frequency of mosaic pathogenic variants in genes causing epilepsy-related neurodevelopmental disorders. Genet. Med. https://doi.org/10.1038/gim.2017.114 (2017)
pubmed: 28837158 pmcid: 5895461 doi: 10.1038/gim.2017.114
King, D. A. et al. Detection of structural mosaicism from targeted and whole-genome sequencing data. Genome Res. 27, 1704–1714 (2017).
pubmed: 28855261 pmcid: 5630034 doi: 10.1101/gr.212373.116
King, D. A. et al. Mosaic structural variation in children with developmental disorders. Hum. Mol. Genet. 24, 2733–2745 (2015).
pubmed: 25634561 pmcid: 4406290 doi: 10.1093/hmg/ddv033
Papavassiliou, P., Charalsawadi, C., Rafferty, K. & Jackson-Cook, C. Mosaicism for trisomy 21: a review. Am. J. Med. Genet. A 167A, 26–39 (2015).
pubmed: 25412855 doi: 10.1002/ajmg.a.36861
Delhanty, J. D. A. Inherited aneuploidy: germline mosaicism. Cytogenet Genome Res 133, 136–140 (2011).
pubmed: 21487228 doi: 10.1159/000323606
Conlin, L. K. et al. Mechanisms of mosaicism, chimerism and uniparental disomy identified by single nucleotide polymorphism array analysis. Hum. Mol. Genet. 19, 1263–1275 (2010).
pubmed: 20053666 pmcid: 3146011 doi: 10.1093/hmg/ddq003
Krupp, D. R. et al. Exonic mosaic mutations contribute risk for autism spectrum disorder. Am. J. Hum. Genet. 101, 369–390 (2017).
pubmed: 28867142 pmcid: 5590950 doi: 10.1016/j.ajhg.2017.07.016
Lim, E. T. et al. Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder. Nat. Neurosci. 20, 1217–1224 (2017).
pubmed: 28714951 pmcid: 5672813 doi: 10.1038/nn.4598
Huisman, S. A., Redeker, E. J. W., Maas, S. M., Mannens, M. M. & Hennekam, R. C. M. High rate of mosaicism in individuals with Cornelia de Lange syndrome. J. Med. Genet. 50, 339–344 (2013).
pubmed: 23505322 doi: 10.1136/jmedgenet-2012-101477
Qin, L. et al. Detection and quantification of mosaic mutations in disease genes by next-generation sequencing. J. Mol. Diagn. 18, 446–453 (2016).
pubmed: 26944031 doi: 10.1016/j.jmoldx.2016.01.002
Gajecka, M. Unrevealed mosaicism in the next-generation sequencing era. Mol. Genet. Genom. 291, 513–530 (2016).
doi: 10.1007/s00438-015-1130-7
Metzker, M. L. Sequencing technologies—the next generation. Nat. Rev. Genet. 11, 31–46 (2010).
pubmed: 19997069 doi: 10.1038/nrg2626
Rios, J. J. & Delgado, M. R. Using whole-exome sequencing to identify variants inherited from mosaic parents. Eur. J. Hum. Genet. 23, 547–550 (2015).
pubmed: 24986828 doi: 10.1038/ejhg.2014.125
Contini, E. et al. A systematic assessment of accuracy in detecting somatic mosaic variants by deep amplicon sequencing: application to NF2 gene. PLoS ONE 10, e0129099 (2015).
pubmed: 26066488 pmcid: 4466335 doi: 10.1371/journal.pone.0129099
de Lange, I. M. et al. Mosaicism of de novo pathogenic SCN1A variants in epilepsy is a frequent phenomenon that correlates with variable phenotypes. Epilepsia 59, 690–703 (2018).
pubmed: 29460957 doi: 10.1111/epi.14021
Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature 542, 433–438 (2017).
doi: 10.1038/nature21062
Wright, C. F. et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Lancet 385, 1305–1314 (2015).
pubmed: 25529582 pmcid: 4392068 doi: 10.1016/S0140-6736(14)61705-0
Wright, C. F. et al. Making new genetic diagnoses with old data: iterative reanalysis and reporting from genome-wide data in 1,133 families with developmental disorders. Genet. Med. 20, 1216–1223 (2018).
pubmed: 29323667 pmcid: 5912505 doi: 10.1038/gim.2017.246
Firth, H. V. & Wright, C. F., DDD Study. The deciphering developmental disorders (DDD) study. Dev. Med. Child Neurol. 53, 702–703 (2011).
pubmed: 21679367 doi: 10.1111/j.1469-8749.2011.04032.x
Marini, C., Mei, D., Helen Cross, J. & Guerrini, R. Mosaic SCN1A mutation in familial severe myoclonic epilepsy of infancy. Epilepsia 47, 1737–1740 (2006).
pubmed: 17054697 doi: 10.1111/j.1528-1167.2006.00675.x
Nakayama, T. et al. Somatic mosaic deletions involving SCN1A cause Dravet syndrome. Am. J. Med. Genet. A 176, 657–662 (2018).
pubmed: 29341473 doi: 10.1002/ajmg.a.38596
Meisler, M. H. et al. SCN8A encephalopathy: research progress and prospects. Epilepsia 57, 1027–1035 (2016).
pubmed: 27270488 pmcid: 5495462 doi: 10.1111/epi.13422
Wall, J. D. et al. Estimating genotype error rates from high-coverage next-generation sequence data. Genome Res. 24, 1734–1739 (2014).
pubmed: 25304867 pmcid: 4216915 doi: 10.1101/gr.168393.113
Jónsson, H. et al. Parental influence on human germline de novo mutations in 1,548 trios from Iceland. Nature 549, 519–522 (2017).
pubmed: 28959963 doi: 10.1038/nature24018
Snape, K. et al. Mutations in CEP57 cause mosaic variegated aneuploidy syndrome. Nat. Genet. 43, 527–529 (2011).
pubmed: 21552266 pmcid: 3508359 doi: 10.1038/ng.822
Hochstenbach, R. et al. Monosomy 20 mosaicism revealed by extensive karyotyping in blood and skin cells: case report and review of the literature. Cytogenet Genome Res 144, 155–162 (2014).
pubmed: 25502965 doi: 10.1159/000369606
Choufani, S. et al. NSD1 mutations generate a genome-wide DNA methylation signature. Nat. Commun. 6, 10207 (2015).
pubmed: 26690673 doi: 10.1038/ncomms10207
Brzezinski, J. et al. Wilms tumour in Beckwith-Wiedemann Syndrome and loss of methylation at imprinting centre 2: revisiting tumour surveillance guidelines. Eur. J. Hum. Genet. 25, 1031–1039 (2017).
pubmed: 28699632 pmcid: 5558170 doi: 10.1038/ejhg.2017.102
Butcher, D. T. et al. CHARGE and Kabuki Syndromes: gene-specific dna methylation signatures identify epigenetic mechanisms linking these clinically overlapping conditions. Am. J. Hum. Genet. 100, 773–788 (2017).
pubmed: 28475860 pmcid: 5420353 doi: 10.1016/j.ajhg.2017.04.004
Jamuar, S. S. et al. Somatic mutations in cerebral cortical malformations. N. Engl. J. Med. 371, 733–743 (2014).
pubmed: 25140959 pmcid: 4274952 doi: 10.1056/NEJMoa1314432
Hiatt, J. B., Pritchard, C. C., Salipante, S. J., O’Roak, B. J. & Shendure, J. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res. 23, 843–854 (2013).
pubmed: 23382536 pmcid: 3638140 doi: 10.1101/gr.147686.112
Kennedy, S. R. et al. Detecting ultralow-frequency mutations by duplex sequencing. Nat. Protoc. 9, 2586–2606 (2014).
pubmed: 25299156 pmcid: 4271547 doi: 10.1038/nprot.2014.170
Yang, X. et al. Genomic mosaicism in paternal sperm and multiple parental tissues in a Dravet syndrome cohort. Sci. Rep. 7, 15677 (2017).
pubmed: 29142202 pmcid: 5688122 doi: 10.1038/s41598-017-15814-7
Bragin, E. et al. DECIPHER: database for the interpretation of phenotype-linked plausibly pathogenic sequence and copy-number variation. Nucleic Acids Res. 42, D993–D1000 (2014).
pubmed: 24150940 doi: 10.1093/nar/gkt937
Köhler, S. et al. The human phenotype ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res. 42, D966–D974 (2014).
pubmed: 24217912 doi: 10.1093/nar/gkt1026
Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature 519, 223–228 (2015).
doi: 10.1038/nature14135
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168 pmcid: 2705234 doi: 10.1093/bioinformatics/btp324
McKenna, A. et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
pubmed: 20644199 pmcid: 2928508 doi: 10.1101/gr.107524.110
Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 19505943 pmcid: 2723002 doi: 10.1093/bioinformatics/btp352
Ramu, A. et al. DeNovoGear: de novo indel and point mutation discovery and phasing. Nat. Methods 10, 985–987 (2013).
pubmed: 23975140 pmcid: 4003501 doi: 10.1038/nmeth.2611
1000 Genomes Project Consortium. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 (2012).
doi: 10.1038/nature11632
UK10K Consortium. et al. The UK10K project identifies rare variants in health and disease. Nature 526, 82–90 (2015).
doi: 10.1038/nature14962
Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
pubmed: 27535533 pmcid: 5018207 doi: 10.1038/nature19057
McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122 (2016).
pubmed: 27268795 pmcid: 4893825 doi: 10.1186/s13059-016-0974-4
Samocha, K. E. et al. A framework for the interpretation of de novo mutation in human disease. Nat. Genet. 46, 944–950 (2014).
pubmed: 25086666 pmcid: 4222185 doi: 10.1038/ng.3050
Thorvaldsdóttir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178–192 (2013).
doi: 10.1093/bib/bbs017

Auteurs

C F Wright (CF)

Institute of Biomedicine and Clinical Science, College of Medicine and Health, University of Exeter, RILD Building, Royal Devon and Exeter Hospital, Exeter, EX2 5DW, UK. caroline.wright@exeter.ac.uk.

E Prigmore (E)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.

D Rajan (D)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.

J Handsaker (J)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.

J McRae (J)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.

J Kaplanis (J)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.

T W Fitzgerald (TW)

European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Cambridge, CB10 1SD, UK.

D R FitzPatrick (DR)

MRC Human Genetics Unit, University of Edinburgh, Edinburgh, EH4 2XU, UK.

H V Firth (HV)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Clinical Genetics, Box 134 Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK.

M E Hurles (ME)

Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH